Prof. Schibli's expertise cover targeted radionuclides diagnosis and therapy with various biomolecules. Apart from the chemical modification and radioactive labeling of molecules, his group emphasizes on the biological and pharmacological characterization and optimization of the radioactive compounds including non-invasive PET and SPET imaging. Furthermore, he provides expertise in the production and application and chemistry of new medically relevant radionuclides for pre-clinical and clinical use.